申请人:Zeneca Limited
公开号:US05527793A1
公开(公告)日:1996-06-18
The present invention relates to carbapenems and provides a compound of the formula (I) ##STR1## wherein: R.sup.1 is 1-hydroxyethyl, 1-fluoroethyl or hydroxymethyl; R.sup.2 is hydrogen or C.sub.1-4 alkyl; R.sup.3 is hydrogen or C.sub.1-4 alkyl; A is a 5-membered heteroaryl ring containing one nitrogen atom and up to two additional heteroatoms selected from nitrogen, oxygen and sulphur; and is bonded to the nitrogen of the linking carbamoyl group by a carbon atom in the ring, is substituted with the carboxy group on a carbon atom in the ring and is optionally further substituted on a carbon atom in the ring; and in any ring --NH--, H is optionally replaced by C.sub.1-4 alkyl; or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof. Processes for their preparation, intermediates in their preparation, their use as therapeutic agents and pharmaceutical compositions containing them are also described.
本发明涉及碳青霉烷类化合物,并提供以下式(I)的化合物:##STR1##
其中:R.sup.1是1-羟乙基,1-氟乙基或羟甲基;R.sup.2是氢或C.sub.1-4烷基;R.sup.3是氢或C.sub.1-4烷基;A是一个含有一个氮原子和最多两个其他杂原子(从氮、氧和硫中选择)的5-成员杂环芳基环,并通过环中的碳原子与连接的氨基甲酰基团的氮原子相连,被环中的碳原子上的羧基取代,并可在环中的碳原子上进一步取代;在任何环中--NH--,H可被C.sub.1-4烷基替换;或其药学上可接受的盐或体内可水解的酯。还描述了它们的制备过程,制备中间体,它们作为治疗剂的用途以及含有它们的制药组合物。